Meet our leadership team

Chief Executive Officer Dustin Haines brings 25 years of experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. Most recently, Mr. Haines was head of Asia, Middle East, Turkey, and Russia for Gilead Sciences where he managed over $1.2B in revenue. As a leader, Mr. Haines has launched innovative technologies globally with extensive experience in regulatory approvals, reimbursement, commercialization, and scaling businesses.

Sam Dribin is a seasoned Chief Technology Officer (CTO) with deep expertise in biotech software development, AI, DevOps, and cloud architecture. With a strong background in building FDA, ISO-13485, and HIPAA-compliant software, Sam specializes in designing secure, scalable, and regulatory-compliant solutions for healthcare and biotech industries. Sam was the Chief Technology Officer at CureMetrix for nine years, where he oversaw the development and FDA clearances of AI software to help physicians identify breast cancer and arterial calcifications in routine mammograms. Sam has a passion for developing innovative software solutions and has played a key role in the success of previous companies.

Nick Lubbers is a dynamic cardiology and medtech leader with over 20 years of experience pioneering new markets, securing reimbursement, and driving commercial growth for breakthrough cardiovascular technologies. He led the commercial launch of Boston Scientific’s Watchman LAAC device, creating a new market for stroke prevention in atrial fibrillation and drove adoption of HeartFlow’s pioneering FFRct analysis, the first non-invasive CT-derived fractional flow reserve technology. At Tempus AI, he built and scaled the cardiology division to advance AI-driven precision care. Nick brings experience in regulatory navigation, reimbursement strategy, team leadership, and emerging-market adoption to accelerate Echo IQ’s growth in AI-powered cardiology.

Dane Brescacin is a regulatory affairs and quality specialist with over 15 years of experience in the biotechnology and medical technology industries. With a strong background in regulatory, quality, and operations, he has successfully led global regulatory strategies, securing FDA clearances, CE Marks, and TGA approvals. Dane has a deep understanding of international regulatory frameworks across different clinical indications and technologies and has guided cross-functional teams through complex submission processes to ensure compliance and market access.

Patrick O’Shea is a healthcare commercialization executive with more than 30 years of experience building and scaling healthcare businesses across pharmaceuticals, medical devices, diagnostics, and AI-enabled healthcare platforms. Beginning his healthcare career in product management at Schering-Plough, he has since led commercialization strategy, brand launches, and growth initiatives for his global healthcare clients that included GSK, Gilead Sciences, Celgene, Bristol Myers Squibb, Covidien, and GE HealthCare. Through leadership roles at Syneos Health (formerly inVentiv), Fingerpaint Group, and ParaPRO, Patrick has developed commercialization frameworks, operational structures, and revenue models that have enabled these healthcare organizations to scale rapidly, capture new market opportunities and grow market value.